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Abstract
Objective: Primary diffuse leptomeningeal gliomatosis
(PDLg) is a rare neoplasm with a short survival time
of a few months. there is currently no standardized
therapeutic approach for PDLg. 
Material  and  Methods:  we  report  on  a  53-year-old
male  patient  who  presented  with  epileptic  seizures,
gait disturbance, paraparesis and sensory deficits in the
dermatomes t8-10. 
Results: Magnetic resonance imaging (MRI) revealing
numerous  spinal  and  cranial  gadolinium-enhancing
nodules in the meninges and histopathology led us to
diagnose  primary  diffuse  leptomeningeal  gliomatosis
with  wHo  grade  III  astrocytic  cells.  Consecutively,
the  patient  underwent  craniospinal  radiotherapy
(30gy)  and  11  sequential  cycles  of  temozolomide.
this regimen led to partial tumor regression. thirteen
months later, spinal MRI revealed tumor progression.
Second-line chemotherapy with 5 cycles of irinotecan
and bevacizumab did not prevent further clinical dete-
rioration.  the  patient  died  twenty-two  months  after
diagnosis,  being  the  longest  survival  time  described
thus far with respect to PDLg consisting of astrocytic
tumor cells. 
Conclusions: Radiochemotherapy including temozolo-
mide, as established standard therapy for brain malig-
nant astrocytomas, might be valid as a basic therapeu-
tic strategy for this PDLg subtype. 
Key  words: primary diffuse leptomeningeal gliomato-
sis; temozolomide; radio-chemotherapy, malignant as-
trocytic cells, survival time
IntRoDuCtIon
Primary diffuse leptomeningeal gliomatosis (PDLg) is
diagnosed when a glioma is located in the subarach-
noid space, while intraparenchymal tumor lesions are
absent  [1].  PDLg  must  be  distinguished  from  sec-
ondary meningeal gliomatosis resulting from a primary
gliomatous  CnS  tumor.  PDLg  occurs  frequently
along  the  spinal  cord  [2].  PDLg,  especially  when
caused by malignant astrocytic cells, is associated with
very poor survival [3]. a standardized therapy for pa-
tients with PDLg is lacking [4].
we describe a patient with PDLg consisting of ma-
lignant astrocytic cells who underwent combined ra-
dio- and chemotherapy leading to the longest survival
time described in the literature thus far. 
CaSE REPoRt
a 53-year-old man was referred to the Dept. of neu-
rology due to a generalized epileptic seizure and five
months  later  he  presented  with  bilateral  sensory
deficits  at  dermatome  levels  t8-10,  paraparesis 
and gait disturbance. Cerebrospinal fluid (CSf) analy-
sis revealed a high cell count (300/3 cells/ﾵl; refer-
ence range: 5/3 cells/ﾵl) with atypical cells that could
not  be  further  characterized.  t1-weighted  images 
(t1-wI)  revealed  spinal  and  cranial  gd-enhancing
nodules in the leptomeninges (figs. 1a-e) and on t2-
weighted  images  (t2-wI)  an  intramedullary  edema
(fig. 1c). 
three weeks later, intradural biopsy from a gd-en-
hancing nodule at L2-3 level revealed fibrously-thick-
ened meninges infiltrated by malignant astrocytic tu-
mor cells (figs. 2a-c). the tumor was categorized as
primary  diffuse  leptomeningeal  gliomatosis  (PDLg)
confirmed by the Reference Center for Brain tumors
in D￼sseldorf, germany. 
Prior to radiotherapy of the craniospinal axis (4 x
2.5 gy/week, total dose: 30 gy), the patient under-
went 3 cycles of temozolomide (tMz) (cycle 1: 150-
200 mg/m2 tzM, d1-5, q28d). on re-staging, spinal
t1-weighted  images  showed  tumor-lesion  regression
on L5 and spinal t2-wI images demonstrated spinal-
edema regression (compare figs. 1c-d with figs. 1a-b).
three weeks after the completion of radiotherapy the
patient  received  eight  additional  cycles  of  tMz
(200mg/m2 tzM, d1-5, q28d), during which me  nin  -
geal  thickening  of  the  brain  regressed.  However,
spinal MRI thirteen months after starting tMz thera-
py  revealed  meningeal  tumor  progression  at  the  le-
sions on spinal levels C1-2, C7-t2 and t5-8. five cy-
cles of second-line chemotherapy with irinotecan and
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Fig.  1.  note gd-enhanced supra- and in-
fratentorial  meningeal  thickenings  of  the
brain in sagittal t1-w image (a). Prior to ra-
diochemotherapy,  t1-wI  reveals  lep-
tomeningeal gd-enhancement (b) and t2-
wI shows edema of the myelon on levels
C7, t1-2 and t5-6 due to minor tumor ex-
tensions in the adjacent spinal cord (c). fol-
lowing radiochemotherapy, t1-wI displays
reduced  leptomeningeal  gd-enhancement
(d) while t2-wI shows less myelon spinal
edema on those levels (e).
8) Hansen##_Umbruchvorlage  04.08.11  16:00  Seite 416bevacizumab failed to halt further clinical de-
terioration.  the  patient  died  twenty-two
months after the diagnosis of PDLg and ex-
hibited until dead an encouraging Karnovsky
performance status of 60%. an autopsy was
declined. 
DISCuSSIon
the diagnosis of PDLg is usually established
by autopsy but rarely diagnosed prior to death
[1]. PDLg of the oligodendroglial and that of
the  well-differentiated  astrocytic  tumor  type
are associated with a considerably longer me-
dian survival time than that of the malignant
astrocytic tumor type [5]. 
PDLg  was  diagnosed  in  the  aforemen-
tioned case, as we observed on histopatholo-
gy  leptomeningeally-encapsulated  malignant
astrocytic cells without primary attachment to
the spinal cord or brain parenchyma and gd-
enhancing  leptomeningeal  thickening  at  the
base of the brain and spinal level in MRI [6,
7].
various treatment modalities were used for
14 patients suffering from PDLg with malig-
nant astrocytic cells reported in the literature
so far (cf. table 1), demonstrating the lack of
a standardized treatment regimen of PDLg
with malignant astrocytic cells. although the
number of cases is small, the data on their
survival times (cf. table 2) might suggest that
radiotherapy and temozolomide (tMz) as es-
tablished  treatment  for  newly  diagnosed  re-
current anaplastic astrocytomas [8] also seem
to be valid for PDLg with malignant astro-
cytic cells. this concept is supported by the
observation that radiotherapy alone can pro-
long the median survival time of five months
for patients without any specific therapy to a
median survival of 12 months and that inte-
gration of tMz in the chemotherapy alone
may lead to a prolonged median survival of
15 months. the importance of tMz in the
chemotherapy  treatment  of  PDLg  is  sup-
ported  by  the  observation  that  the  median
survival time fell to 3 months when the inte-
gration of tMz was omitted. 
the prolonged survival of our patient may
be due to the addition of tMz to radiation
therapy as it resulted in an extent of the me-
dian survival time for high grade glioma pa-
tients  [9].  In  addition,  the  hypofractionated
radiotherapy regimen used is supposed to be
more effective than conventional fractionated
irradiation.  additionally,  the  patient’s  good
Karnofsky performance status may have con-
tributed to our patient’s prolonged survival.
In conclusion, we report on partial regres-
sion  and  long  survival  in  a  patient  with
PDLg of the malignant astrocytic type fol-
lowing  hypofractionated  radiotherapy  and
tMz.  an  immediate  radiochemotherapy
seems  crucial  for  a  prolonged  survival  of
PDLg patients in good general condition. 
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Fig.  2.  Intradural  lumbar  biopsy  displays  fibrously-thickened  lep-
tomeninges  infiltrated  by  pleomorphic  neoplastic  astrocytic  cells  (a).
the  astrocytic  tumor  cells  reveal  intensive  intracytoplasmic  staining
with anti-glial fibrillary astrocytic protein. (b). Ki67 (MIB-1) staining re-
veals a high proliferation index of up to 20% (c).
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Table 2. Summary of the literature: PDLg with malignant as-
trocytic cells. 
number of cases (including our patient) 15
M: f ratio 12:3
Median age (in years); age range (in years) 43; 19-71
Secondary brain involvement 87% (13/15)
Secondary spinal cord involvement 74% (11/15)
Median survival (in months)  8 (1-24)
Median survival without therapy (in months)  5 (1-7)
Median survival with radiotherapy only  12
(in months)
Median survival with chemotherapy only  3
(in months)
- without temozolomide <3
- including temozolomide 15 
Median survival with radio- und chemotherapy  11
(in months)
- without temozolomide 3
- including temozolomide (our patient) 18
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